Abstract
Introduction
The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
Methods
Virtually all patients prescribed teriparatide in the UK receive treatment through Healthcare at Home, Basingstoke, UK. Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch. Persistence was defined as the number of patients continuing treatment.
Results
A total of 1,104 patients were included in the analysis. The median duration of use in all patients was 252 days. Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%. Forty-two patients (3.8%) had discontinued treatment due to adverse events.
Conclusions
This study demonstrates that persistence with teriparatide at 12 months is very high and is probably greater than that of existing oral therapies for osteoporosis. The reasons for the high persistence rates seen with teriparatide are likely to be multi-factorial. The high persistence rates should help to optimise the effectiveness of therapy in this group of high-risk patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A):12S–17S
Bocuzzi SJ, Folz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16(Suppl 3):Abstract OC10
Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460
McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271–287
Cano A (1994) Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20(2–3):91–99
Kotzan JA, Martin BC, Wade WE (1999) Persistence with oestrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 19(3):363–369
NICE (2004) Secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, England, June 2004
Sackett DL, Snow JC (1981) Magnitude of compliance and non-compliance. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, Maryland, pp 11–23
Papaioannou A, Ioannidid G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14(10):808–813
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14(3):259–262
Kelly R, Taggart H (1997) Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 315(7117):1235
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arden, N.K., Earl, S., Fisher, D.J. et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17, 1626–1629 (2006). https://doi.org/10.1007/s00198-006-0171-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-006-0171-5